Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities (Q33636098)

24900831

28 July 2017

title

Novel 2,4-Diarylaminopyrimidine Analogues (DAAPalogues) Showing Potent c-Met/ALK Multikinase Inhibitory Activities (English)

1 reference

28 July 2017

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jing Ai

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Xia Peng

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Zilan Song

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Kui Wu

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Jing Zhang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Qizheng Yao

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Yi Chen

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Yinchun Ji

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Yanhong Yang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Meiyu Geng

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

Ao Zhang

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

publication date

8 February 2014

1 reference

24900831

ACS Medicinal Chemistry Letters

28 July 2017

published in

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

volume

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

issue

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

page(s)

304-308

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

Discovery of a potent inhibitor of anaplastic lymphoma kinase with in vivo antitumor activity

7 June 2020

cites work

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Design, synthesis, and biological evaluation of a series of benzo[de][1,7]naphthyridin-7(8H)-ones bearing a functionalized longer chain appendage as novel PARP1 inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Update 1 of: Recent progress in development of dopamine receptor subtype-selective agents: potential therapeutics for neurological and psychiatric disorders

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

ALK inhibitors: a new targeted therapy in the treatment of advanced NSCLC.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Multisubstituted quinoxalines and pyrido[2,3-d]pyrimidines: synthesis and SAR study as tyrosine kinase c-Met inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Inhibitors of the anaplastic lymphoma kinase

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

The emerging role of ALK inhibitors in the treatment of advanced non-small cell lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

New strategies for treatment of ALK-rearranged non-small cell lung cancers

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Discovery of novel c-Met kinase inhibitors bearing a thieno[2,3-d]pyrimidine or furo[2,3-d]pyrimidine scaffold

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Insights into ALK-driven cancers revealed through development of novel ALK tyrosine kinase inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

CH5424802, a Selective ALK Inhibitor Capable of Blocking the Resistant Gatekeeper Mutant

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Synthesis and c-Met Kinase Inhibition of 3,5-Disubstituted and 3,5,7-Trisubstituted Quinolines: Identification of 3-(4-Acetylpiperazin-1-yl)-5-(3-nitrobenzylamino)-7- (trifluoromethyl)quinoline as a Novel Anticancer Agent

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

ALK Inhibition for Non-Small Cell Lung Cancer: From Discovery to Therapy in Record Time

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Fused bicyclic derivatives of 2,4-diaminopyrimidine as c-Met inhibitors

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

A mouse model for EML4-ALK-positive lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Dopamine D1 receptor ligands: where are we now and where are we going

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Drug development of MET inhibitors: targeting oncogene addiction and expedience

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Cytoreductive antitumor activity of PF-2341066, a novel inhibitor of anaplastic lymphoma kinase and c-Met, in experimental models of anaplastic large-cell lymphoma

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Global survey of phosphotyrosine signaling identifies oncogenic kinases in lung cancer

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

An orally available small-molecule inhibitor of c-Met, PF-2341066, exhibits cytoreductive antitumor efficacy through antiproliferative and antiangiogenic mechanisms

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Identification of NVP-TAE684, a potent, selective, and efficacious inhibitor of NPM-ALK.

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Improvement in oral bioavailability of 2,4-diaminopyrimidine c-Met inhibitors by incorporation of a 3-amidobenzazepin-2-one group

21 June 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

2,4-Diaminopyrimidine inhibitors of c-Met kinase bearing benzoxazepine anilines.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Novel 2,3,4,5-tetrahydro-benzo[d]azepine derivatives of 2,4-diaminopyrimidine, selective and orally bioavailable ALK inhibitors with antitumor efficacy in ALCL mouse models

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

EML4-ALK: honing in on a new target in non-small-cell lung cancer.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Dopamine/serotonin receptor ligands. Part IV [1]: synthesis and pharmacology of novel 3-benzazecines and 3-benzazonines as potential 5-HT2A and dopamine receptor ligands.

30 October 2018

1 reference

https://eutils.ncbi.nlm.nih.gov/entrez/eutils/elink.fcgi?dbfrom=pmc&linkname=pmc_refs_pubmed&retmode=json&id=4027579

Methanesulfonamido-cyclohexylamine derivatives of 2,4-diaminopyrimidine as potent ALK inhibitors

30 October 2018

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24900831

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Detection of anaplastic lymphoma kinase (ALK) and nucleolar protein nucleophosmin (NPM)-ALK proteins in normal and neoplastic cells with the monoclonal antibody ALK1

1 reference

PubMed

https://pubmed.ncbi.nlm.nih.gov/24900831

inferred from PubMed ID database lookup

12 December 2020

based on heuristic

Identifiers

DOI

10.1021/ML400373J

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json

7 June 2020

24900831

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:24900831%20AND%20SRC:MED&resulttype=core&format=json